Global pharma brands ranked for strength and value in 2022

9 May 2022
digital_marketing_big

Marketing firm Brand Finance has released its  annual report assessing the strength and value of brands in the pharma and biotech sectors.

The company has looked at the world’s biggest brands to create a ranking based on its assessment of their global impact and significance to consumers.

The group finds that Johnson & Johnson (NYSE: JNJ) has the most valuable brand, with a valuation of $13.3 billion, followed by Swiss cancer giant Roche (ROG: SIX), at $9 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical